PharmAthene Company Profile (NYSE:PIP)

About PharmAthene (NYSE:PIP)

PharmAthene logoPharmathene, Inc. (Pharmathene) is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.

Industry, Sector and Symbol:
  • Sector: Finance
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSE:PIP
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $0.77
  • 200 Day Moving Avg: $2.08
  • 52 Week Range: $0.47 - $3.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.29
  • P/E Growth: 0.00
Misc:
  • Average Volume: 4.43 million shs.
 
Frequently Asked Questions for PharmAthene (NYSE:PIP)

What is PharmAthene's stock symbol?

PharmAthene trades on the New York Stock Exchange (NYSE) under the ticker symbol "PIP."

How often does PharmAthene pay dividends? What is the dividend yield for PharmAthene?

PharmAthene declared a special dividend on Monday, November 21st. Investors of record on Sunday, January 24th will be given a dividend of $2.91 per share on Friday, February 3rd. The ex-dividend date of this dividend is Monday, February 6th. View PharmAthene's Dividend History.

How were PharmAthene's earnings last quarter?

PharmAthene, Inc. (NYSE:PIP) posted its quarterly earnings results on Monday, March, 9th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $1.83 million for the quarter. View PharmAthene's Earnings History.

Who are some of PharmAthene's key competitors?

Who owns PharmAthene stock?

PharmAthene's stock is owned by many different of retail and institutional investors. Top institutional investors include NOVARTIS BIOVENTURES LTD (11.10%) and TRUFFLE CAPITAL S.A.S. (10.10%). Company insiders that own PharmAthene stock include Eric I Richman and Prescott Group Capital Managem. View Institutional Ownership Trends for PharmAthene.

How do I buy PharmAthene stock?

Shares of PharmAthene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PharmAthene's stock price today?

One share of PharmAthene stock can currently be purchased for approximately $0.65.


MarketBeat Community Rating for PharmAthene (NYSE PIP)
Community Ranking:  2.1 out of 5 ( )
Outperform Votes:  20 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  47
MarketBeat's community ratings are surveys of what our community members think about PharmAthene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for PharmAthene (NYSE:PIP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for PharmAthene (NYSE:PIP)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for PharmAthene (NYSE:PIP)
Earnings by Quarter for PharmAthene (NYSE:PIP)
Earnings History by Quarter for PharmAthene (NYSE PIP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2015($0.03)($0.04)$1.83 millionViewN/AView Earnings Details
11/6/2014($0.03)($0.07)$3.50 million$0.96 millionViewN/AView Earnings Details
8/4/2014($0.06)($0.01)$3.66 millionViewN/AView Earnings Details
5/8/2014($0.06)($0.04)$3.74 millionViewN/AView Earnings Details
3/11/2014Q4($0.05)($0.08)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for PharmAthene (NYSE:PIP)
Current Year EPS Consensus Estimate: $-0.10 EPS
Next Year EPS Consensus Estimate: $-0.07 EPS

Dividends

Current Dividend Information for PharmAthene (NYSE:PIP)
Most Recent Dividend:2/3/2017
Dividend Yield:0.00%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:0.00% (Based on This Year's Estimates)
0.00% (Based on Next Year's Estimates)
Dividend Payments by Quarter for PharmAthene (NYSE:PIP)

Dividend History by Quarter for PharmAthene (NYSE PIP)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/21/2016special$2.912/6/20171/24/20162/3/2017
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for PharmAthene (NYSE:PIP)
Insider Trades by Quarter for PharmAthene (NYSE:PIP)
Insider Trades by Quarter for PharmAthene (NYSE:PIP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Prescott Group Capital ManagemMajor ShareholderSell1,354,632$3.26$4,416,100.32View SEC Filing  
4/13/2016Eric I RichmanDirectorSell329,354$2.20$724,578.80View SEC Filing  
4/8/2016Eric I RichmanDirectorSell11,767$2.20$25,887.40View SEC Filing  
3/19/2015Peter Steven StDirectorBuy25,000$1.65$41,250.00View SEC Filing  
1/7/2015Linda L ChangCFOSell29,600$2.10$62,160.00View SEC Filing  
9/22/2014Prescott Group Capital ManagemMajor ShareholderBuy15,000$1.55$23,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for PharmAthene (NYSE:PIP)
Latest Headlines for PharmAthene (NYSE:PIP)
Source:
DateHeadline
americanbankingnews.com logoPharmAthene, Inc. (PIP) Sees Large Decrease in Short Interest
www.americanbankingnews.com - May 10 at 7:00 AM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: AVEO Pharmaceuticals and PharmAthene
finance.yahoo.com - May 5 at 8:41 AM
americanbankingnews.com logoPharmAthene (PIP) Earning Positive Media Coverage, Study Shows
www.americanbankingnews.com - May 4 at 2:56 PM
finance.yahoo.com logoPharmAthene reports 1Q loss
finance.yahoo.com - May 4 at 8:15 AM
prnewswire.com logoPharmAthene Reports First Quarter 2017 Financial and Operational Results - PR Newswire (press release)
www.prnewswire.com - May 3 at 7:47 PM
finance.yahoo.com logoPharmAthene Reports First Quarter 2017 Financial and Operational Results
finance.yahoo.com - May 3 at 7:47 PM
americanbankingnews.com logoPharmAthene (PIP) Earns Daily Media Sentiment Score of 0.21
www.americanbankingnews.com - April 30 at 5:45 PM
americanbankingnews.com logoPharmAthene (PIP) Given News Impact Score of 0.01
www.americanbankingnews.com - April 27 at 6:50 PM
streetinsider.com logoPharmAthene (PIP), Altimmune Combination Approved to Trade on Nasdaq Global Under Ticker ALT (ALT)
www.streetinsider.com - April 26 at 11:06 PM
streetinsider.com logoPharmAthene (PIP), Altimmune Combination Approved to Trade on Nasdaq Global Under Ticker ALT (ALT) - StreetInsider.com
www.streetinsider.com - April 26 at 6:02 PM
finance.yahoo.com logoPharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market
finance.yahoo.com - April 26 at 6:02 PM
finance.yahoo.com logoETFs with exposure to PharmAthene, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 7:13 PM
americanbankingnews.com logoSomewhat Critical Media Coverage Somewhat Likely to Impact PharmAthene (PIP) Share Price
www.americanbankingnews.com - April 17 at 5:01 PM
americanbankingnews.com logoPharmAthene (PIP) Given Daily News Impact Score of -0.10
www.americanbankingnews.com - April 14 at 1:08 PM
americanbankingnews.com logoPharmAthene, Inc. (PIP) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 11 at 7:11 PM
finance.yahoo.com logoETFs with exposure to PharmAthene, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 7:37 PM
biz.yahoo.com logoPHARMATHENE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - March 29 at 7:58 PM
finance.yahoo.com logoAltimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™
finance.yahoo.com - March 28 at 9:44 AM
americanbankingnews.com logoPharmAthene, Inc. (PIP) Short Interest Update
www.americanbankingnews.com - March 25 at 7:14 AM
finance.yahoo.com logoPHARMATHENE, INC Financials
finance.yahoo.com - March 18 at 6:36 PM
finance.yahoo.com logoPharmAthene Reports Year-End 2016 Financial and Operational Results
finance.yahoo.com - March 14 at 6:44 PM
biz.yahoo.com logoPHARMATHENE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statement
biz.yahoo.com - March 14 at 6:44 PM
finance.yahoo.com logoPharmAthene Announces Record Date and Meeting Date for Special Meeting of Stockholders Regarding Proposed Merger Transaction with Altimmune
finance.yahoo.com - March 13 at 9:46 AM
americanbankingnews.com logoPharmAthene, Inc. (PIP) Short Interest Down 56.8% in February
www.americanbankingnews.com - March 9 at 6:30 PM
finance.yahoo.com logoPepsico CFO: We have terrific momentum
finance.yahoo.com - February 16 at 6:51 PM
finance.yahoo.com logoPepsico CFO: Great business in Mexico
finance.yahoo.com - February 16 at 6:51 PM
thestreet.com logoBiotech Premarket Movers: PharmAthene, Earth Science Tech, Pulmatrix
www.thestreet.com - February 7 at 9:03 PM
finance.yahoo.com logoAltimmune to Present at the BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:06 AM
streetinsider.com logoForm 425 PHARMATHENE, INC Filed by: PHARMATHENE, INC
www.streetinsider.com - February 1 at 9:41 PM
wsj.com logo[$$] Gormley's Take: As IPO Market Tightens, Biotechs Find Another Route to Public Listing
www.wsj.com - February 1 at 9:41 PM
investopedia.com logoPharmAthene and Altimmune to Merge in All-Stock Deal
www.investopedia.com - January 23 at 7:33 PM
bizjournals.com logoTwo of region's anthrax-fighting companies announce merger
us.rd.yahoo.com - January 20 at 8:05 PM
streetinsider.com logoPharmAthene (PIP), Altimmune to Merge in All-Stock Transaction - StreetInsider.com
www.streetinsider.com - January 20 at 1:18 AM
finance.yahoo.com logoPharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
finance.yahoo.com - January 20 at 1:18 AM
finance.yahoo.com logo6:32 am PharmAthene and privately-held Altimmune announce merger in an all-stock transaction
finance.yahoo.com - January 20 at 1:17 AM
biz.yahoo.com logoPHARMATHENE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Off
biz.yahoo.com - January 20 at 1:17 AM
feeds.benzinga.com logoMid-Afternoon Market Update: Dow Slides Over 100 Points; CSX Shares Spike Higher
feeds.benzinga.com - January 19 at 4:05 PM

Social

Chart

PharmAthene (PIP) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff